Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Deregistered. Lunai Bioworks ended its SEC registration on Nov 12, 2026 (Form 15-12G) and no longer files reports. The data below may be out of date. Read the filing
$1.7MCash on Hand
3.6mo Cash Runway
14.8%Short Interest
Follow LNAI by emailGet an email when LNAI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LNAI, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Oct 23, 2026 ·
Listing Nasdaq notified Lunai that it fails the $2.5 million stockholders' equity rule, citing a $(9,024,946) deficit, and trading is expected to be suspended October 30, 2026. The Board approved voluntary delisting and deregistration, with the Form 25 expected around November 2 and delisting around November 12. Form 8-K · SEC filing · Press release
Oct 13, 2026 ·
Annual report for the period ended Jun 30, 2026 Form 10-K · SEC filing
Oct 9, 2026 ·
Legal Lunai Bioworks asked Nasdaq on October 9, 2026 to immediately suspend trading in its common stock, citing trading records from its pending Delaware litigation against Seven Points Capital LLC et al. Nasdaq has not yet responded, and the request does not itself halt trading. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
LNAI holds $1.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.4M/quarter from operations,
an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LNAI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.